The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions.

IF 2.5 2区医学 Q2 UROLOGY & NEPHROLOGY

Current Urology Reports Pub Date : 2025-05-31 DOI:10.1007/s11934-025-01268-2

Raeesa Islam, Shrijal Desai, Melissa Moran, David M Golombos

{"title":"The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions.","authors":"Raeesa Islam, Shrijal Desai, Melissa Moran, David M Golombos","doi":"10.1007/s11934-025-01268-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has revolutionized prostate cancer detection and management. This review aims to evaluate the latest advancements in PSMA PET imaging, assess its clinical applications in various disease stages, and compare it to conventional imaging techniques. We sought to determine how PSMA PET impacts clinical decision-making, treatment strategies, and patient outcomes, with a focus on its expanding role in precision oncology.Recent findings: Recent studies have demonstrated that PSMA PET exhibits superior sensitivity and specificity in detecting prostate cancer metastases, particularly in cases of biochemical recurrence and early-stage disease. The advent of radiolabeled PSMA ligands, such as 68Ga-PSMA-11 and 18 F-DCFPyL, has led to improved diagnostic accuracy. Furthermore, PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-617) show promising results in metastatic castration-resistant prostate cancer (mCRPC), offering a novel therapeutic avenue. Studies have also highlighted the role of PSMA PET in refining treatment plans, including guiding surgery and radiotherapy. PSMA PET imaging represents a paradigm shift in prostate cancer diagnostics, staging, and treatment monitoring. It has led to earlier and more accurate detection of metastases, significantly altering management strategies. The growing body of evidence supports its integration into standard-of-care protocols, with ongoing research focusing on optimizing its therapeutic applications. Future studies should explore cost-effectiveness, accessibility, and potential synergies with emerging systemic therapies to further enhance patient outcomes.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"46"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126340/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-025-01268-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has revolutionized prostate cancer detection and management. This review aims to evaluate the latest advancements in PSMA PET imaging, assess its clinical applications in various disease stages, and compare it to conventional imaging techniques. We sought to determine how PSMA PET impacts clinical decision-making, treatment strategies, and patient outcomes, with a focus on its expanding role in precision oncology.

Recent findings: Recent studies have demonstrated that PSMA PET exhibits superior sensitivity and specificity in detecting prostate cancer metastases, particularly in cases of biochemical recurrence and early-stage disease. The advent of radiolabeled PSMA ligands, such as 68Ga-PSMA-11 and 18 F-DCFPyL, has led to improved diagnostic accuracy. Furthermore, PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-617) show promising results in metastatic castration-resistant prostate cancer (mCRPC), offering a novel therapeutic avenue. Studies have also highlighted the role of PSMA PET in refining treatment plans, including guiding surgery and radiotherapy. PSMA PET imaging represents a paradigm shift in prostate cancer diagnostics, staging, and treatment monitoring. It has led to earlier and more accurate detection of metastases, significantly altering management strategies. The growing body of evidence supports its integration into standard-of-care protocols, with ongoing research focusing on optimizing its therapeutic applications. Future studies should explore cost-effectiveness, accessibility, and potential synergies with emerging systemic therapies to further enhance patient outcomes.

查看原文本刊更多论文

PSMA PET成像在前列腺癌中的作用：目前的应用和未来的方向。

综述目的：前列腺特异性膜抗原（PSMA）靶向正电子发射断层扫描（PET）成像已经彻底改变了前列腺癌的检测和治疗。本文综述PSMA PET成像的最新进展，评估其在不同疾病阶段的临床应用，并将其与传统成像技术进行比较。我们试图确定PSMA PET如何影响临床决策、治疗策略和患者预后，重点关注其在精确肿瘤学中的扩展作用。最近的发现：最近的研究表明，PSMA PET在检测前列腺癌转移方面表现出优越的敏感性和特异性，特别是在生化复发和早期疾病的情况下。放射性标记PSMA配体的出现，如68Ga-PSMA-11和18f - dcfpyl，提高了诊断的准确性。此外，psma靶向放射配体疗法（如177Lu-PSMA-617）在转移性去势抵抗性前列腺癌（mCRPC）中显示出有希望的结果，提供了一种新的治疗途径。研究还强调了PSMA PET在完善治疗计划中的作用，包括指导手术和放疗。PSMA PET成像代表了前列腺癌诊断、分期和治疗监测的范式转变。它导致更早、更准确地发现转移，显著改变了治疗策略。越来越多的证据支持将其纳入标准治疗方案，正在进行的研究侧重于优化其治疗应用。未来的研究应该探索成本效益、可及性以及与新兴系统疗法的潜在协同作用，以进一步提高患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Urology Reports UROLOGY & NEPHROLOGY-

CiteScore

4.60

自引率

3.80%

发文量

期刊介绍： This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.